Axonics, Inc. (AXNX) Tops Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St set to open lower as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Goldman sees central bank demand providing a floor for gold prices
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
Axonics Reports Third Quarter 2023 Financial Results
October 30, 2023 4:01 PM EDTGenerated quarterly revenue of $93.1 million, an increase of 32% year over year
Fiscal year 2023 revenue guidance increased to $362 million
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023.
Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter, said Raymond W. Cohen, chief executive officer. Our... More
